Radiation-induced pulmonary gene expression changes are attenuated by the CTGF antibody Pamrevlumab.

Autor: Sternlicht MD; FibroGen, Inc., San Francisco, USA., Wirkner U; Department of Translational Radiooncology, German Cancer Research Center (DKFZ), Heidelberg, Germany., Bickelhaupt S; Department of Radiology, DKFZ, Heidelberg, Germany., Lopez Perez R; Department of Molecular and Radiation Oncology, DKFZ, Heidelberg, Germany., Tietz A; Department of Molecular and Radiation Oncology, DKFZ, Heidelberg, Germany., Lipson KE; FibroGen, Inc., San Francisco, USA. klipson@fibrogen.com., Seeley TW; FibroGen, Inc., San Francisco, USA., Huber PE; Department of Molecular and Radiation Oncology, DKFZ, Heidelberg, Germany.; Department of Radiation Oncology, University Hospital Center, Heidelberg, Germany.
Jazyk: angličtina
Zdroj: Respiratory research [Respir Res] 2018 Jan 18; Vol. 19 (1), pp. 14. Date of Electronic Publication: 2018 Jan 18.
DOI: 10.1186/s12931-018-0720-4
Abstrakt: Background: Fibrosis is a delayed side effect of radiation therapy (RT). Connective tissue growth factor (CTGF) promotes the development of fibrosis in multiple settings, including pulmonary radiation injury.
Methods: To better understand the cellular interactions involved in RT-induced lung injury and the role of CTGF in these responses, microarray expression profiling was performed on lungs of irradiated and non-irradiated mice, including mice treated with the anti-CTGF antibody pamrevlumab (FG-3019). Between group comparisons (Welch's t-tests) and principal components analyses were performed in Genespring.
Results: At the mRNA level, the ability of pamrevlumab to prolong survival and ameliorate RT-induced radiologic, histologic and functional lung deficits was correlated with the reversal of a clear enrichment in mast cell, macrophage, dendritic cell and mesenchymal gene signatures. Cytokine, growth factor and matrix remodeling genes that are likely to contribute to RT pneumonitis and fibrosis were elevated by RT and attenuated by pamrevlumab, and likely contribute to the cross-talk between enriched cell-types in injured lung.
Conclusions: CTGF inhibition had a normalizing effect on select cell-types, including immune cells not typically regarded as being regulated by CTGF. These results suggest that interactions between RT-recruited cell-types are critical to maintaining the injured state; that CTGF plays a key role in this process; and that pamrevlumab can ameliorate RT-induced lung injury in mice and may provide therapeutic benefit in other immune and fibrotic disorders.
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje